Human antiviral 'GS-441524' shows great promise against infectious disease in cats

ScienceDaily | 2/13/2019 | Staff
darkkazunedarkkazune (Posted by) Level 3
Thirty-one cats, ranging in age from 3-73 months, were enrolled in the study, and 26 completed the planned 12 weeks or more of treatment; the remainder died or were euthanized due to their severe disease. For these 26 cats, the clinical response was dramatic: fever usually resolved within 12-36 h, concurrent with a marked improvement in appetite, activity levels and weight gain. In cats with the more common effusive or 'wet' form of FIP, abdominal effusions rapidly disappeared, starting at around 10-14 days after commencing treatment. Encouragingly, and somewhat unexpectedly, cats with non-effusive ('dry') FIP and older cats responded as well to GS-441524 treatment as did cats with effusive FIP and young cats. The safety profile of GS-441524 was likewise impressive.

Currently, 24 of the 26 cats remain healthy, with one having succumbed to FIP disease and one to unrelated heart disease. Eighteen of these cats underwent just one round of treatment; the remaining eight suffered disease relapses, but these were successfully treated with a further (in two cases, a third) round of treatment at a higher dose.

Prospects - Cats - FIP - Review - Paper

Previously the prospects for cats with FIP were bleak. In a seminal review paper on FIP published in JFMS a decade ago, Professor Pedersen stated:...
(Excerpt) Read more at: ScienceDaily
Wake Up To Breaking News!
Sign In or Register to comment.

Welcome to Long Room!

Where The World Finds Its News!